
Portable receiver for displaying and storing measured values from the HemoPill® acute.
+49 (0) 7071 96528 160
service@ovesco.com
+49 (0) 7071 96528 160
service@ovesco.com
The HemoPill® Receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute. The measured values are transmitted wirelessly in real time from the HemoPill® acute to the HemoPill® Receiver.
The HemoPill® Receiver has a colour display with touchscreen. The menu navigation is straightforward and allows for easy data access. Due to the integrated battery, the HemoPill® Receiver is transportable and thus enables user-friendly handling.
The corresponding thermal printer (HemoPill® Printer) can be connected via the designated USB port on the side of the HemoPill® Receiver to print out the findings.
Please note: The HemoPill® acute is not for sale in the US.
20 minutes after swallowing the HemoPill® acute, a significant increase in the HI value was observed. This indicated acute bleeding in the upper digestive tract. The examination using the HemoPill® was completed after 43 minutes and a gastroscopy was performed immediately. This showed a bleeding angiodysplasia in a gastrojejunal anastomosis, which was successfully treated.
The significant increase in the HI value after 2.5 hours was indication of bleeding in the middle digestive tract. The examination took a total of 9 hours. A subsequent targeted double balloon enteroscopy showed angiodysplasia in the small intestine, which was treated successfully.
Use of the HemoPill® acute in the early clinical phase (July 2019 – September 2020)
Source: Prof. Dr. Arthur R. Schmidt and Dr. Armin Kuellmer, Medical Center – University of Freiburg, Germany / Prof. Dr. Juergen Hochberger and Dr. Thomas Brunk, Vivantes Klinikum im Friedrichshain, Germany
No increase in the HI value was observed after the capsule was swallowed. Further differential diagnostics identified an aortic dissection as the cause of the anaemia detected in the emergency room. This meant that the patient did not need to undergo an endoscopy.
Use of the HemoPill® acute in the early clinical phase (July 2019 – September 2020)
Source: Prof. Dr. Arthur R. Schmidt and Dr. Armin Kuellmer, Medical Center – University of Freiburg, Germany / Prof. Dr. Juergen Hochberger and Dr. Thomas Brunk, Vivantes Klinikum im Friedrichshain, Germany